Literature DB >> 17696217

Long-term neurological and functional outcome in Nipah virus infection.

James J Sejvar1, Jahangir Hossain, Sankar Kama Saha, Emily S Gurley, Shakila Banu, Jena D Hamadani, Mohammed Abdul Faiz, F M Siddiqui, Quazi Deen Mohammad, Abid Hossain Mollah, Rafique Uddin, Rajibul Alam, Ridwanur Rahman, Chong Tin Tan, William Bellini, Paul Rota, Robert F Breiman, Stephen P Luby.   

Abstract

OBJECTIVE: Nipah virus (NiV) is an emerging zoonosis. Central nervous system disease frequently results in high case-fatality. Long-term neurological assessments of survivors are limited. We assessed long-term neurologic and functional outcomes of 22 patients surviving NiV illness in Bangladesh.
METHODS: During August 2005 and May 2006, we administered a questionnaire on persistent symptoms and functional difficulties to 22 previously identified NiV infection survivors. We performed neurologic evaluations and brain magnetic resonance imaging (MRI).
RESULTS: Twelve (55%) subjects were male; median age was 14.5 years (range 6-50). Seventeen (77%) survived encephalitis, and 5 survived febrile illness. All but 1 subject had disabling fatigue, with a median duration of 5 months (range, 8 days-8 months). Seven encephalitis patients (32% overall), but none with febrile illness had persistent neurologic dysfunction, including static encephalopathy (n = 4), ocular motor palsies (2), cervical dystonia (2), focal weakness (2), and facial paralysis (1). Four cases had delayed-onset neurologic abnormalities months after acute illness. Behavioral abnormalities were reported by caregivers of over 50% of subjects under age 16. MRI abnormalities were present in 15, and included multifocal hyperintensities, cerebral atrophy, and confluent cortical and subcortical signal changes.
INTERPRETATION: Although delayed progression to neurologic illness following Nipah fever was not observed, persistent fatigue and functional impairment was frequent. Neurologic sequelae were frequent following Nipah encephalitis. Neurologic dysfunction may persist for years after acute infection, and new neurologic dysfunction may develop after acute illness. Survivors of NiV infection may experience substantial long-term neurologic and functional morbidity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17696217     DOI: 10.1002/ana.21178

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  42 in total

Review 1.  The immune response to Nipah virus infection.

Authors:  Joseph Prescott; Emmie de Wit; Heinz Feldmann; Vincent J Munster
Journal:  Arch Virol       Date:  2012-06-06       Impact factor: 2.574

Review 2.  Emerging viral infections of the central nervous system: part 2.

Authors:  Kenneth L Tyler
Journal:  Arch Neurol       Date:  2009-09

3.  Investigating Rare Risk Factors for Nipah Virus in Bangladesh: 2001-2012.

Authors:  Sonia T Hegde; Hossain M S Sazzad; M Jahangir Hossain; Mahbub-Ul Alam; Eben Kenah; Peter Daszak; Pierre Rollin; Mahmudur Rahman; Stephen P Luby; Emily S Gurley
Journal:  Ecohealth       Date:  2016-10-13       Impact factor: 3.184

4.  Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge.

Authors:  Michael K Lo; Friederike Feldmann; Joy M Gary; Robert Jordan; Roy Bannister; Jacqueline Cronin; Nishi R Patel; John D Klena; Stuart T Nichol; Tomas Cihlar; Sherif R Zaki; Heinz Feldmann; Christina F Spiropoulou; Emmie de Wit
Journal:  Sci Transl Med       Date:  2019-05-29       Impact factor: 17.956

5.  Hendra virus and Nipah virus animal vaccines.

Authors:  Christopher C Broder; Dawn L Weir; Peter A Reid
Journal:  Vaccine       Date:  2016-05-04       Impact factor: 3.641

6.  A Controlled Trial to Reduce the Risk of Human Nipah Virus Exposure in Bangladesh.

Authors:  Nazmun Nahar; Repon C Paul; Rebeca Sultana; Shariful Amin Sumon; Kajal Chandra Banik; Jaynal Abedin; Mohammad Asaduzzaman; Fernando Garcia; Susan Zimicki; Mahmudur Rahman; Emily S Gurley; Stephen P Luby
Journal:  Ecohealth       Date:  2017-09-13       Impact factor: 3.184

7.  Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry.

Authors:  Matteo Porotto; Barry Rockx; Christine C Yokoyama; Aparna Talekar; Ilaria Devito; Laura M Palermo; Jie Liu; Riccardo Cortese; Min Lu; Heinz Feldmann; Antonello Pessi; Anne Moscona
Journal:  PLoS Pathog       Date:  2010-10-28       Impact factor: 6.823

8.  Transmission of human infection with Nipah virus.

Authors:  Stephen P Luby; Emily S Gurley; M Jahangir Hossain
Journal:  Clin Infect Dis       Date:  2009-12-01       Impact factor: 9.079

9.  Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection.

Authors:  Alexander N Freiberg; Melissa N Worthy; Benhur Lee; Michael R Holbrook
Journal:  J Gen Virol       Date:  2009-11-04       Impact factor: 3.891

10.  Recurrent zoonotic transmission of Nipah virus into humans, Bangladesh, 2001-2007.

Authors:  Stephen P Luby; M Jahangir Hossain; Emily S Gurley; Be Nazir Ahmed; Shakila Banu; Salah Uddin Khan; Nusrat Homaira; Paul A Rota; Pierre E Rollin; James A Comer; Eben Kenah; Thomas G Ksiazek; Mahmudur Rahman
Journal:  Emerg Infect Dis       Date:  2009-08       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.